Skip to main content

Cardiovascular Risk

0
Pipeline Programs
5
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs
No treatment givenN/A1 trial
ZiltivekimabPHASE_3Monoclonal Antibody1 trial
Ziltivekimab BPHASE_31 trial
Active Trials
NCT06122961Completed18,198Est. Apr 2025
NCT06118281Recruiting10,000Est. Dec 2026
NCT05021835Active Not Recruiting6,200Est. Jun 2026
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
Corrie Lipids Digital Health ProgramN/A1 trial
Active Trials
NCT07478887Recruiting1,000Est. Dec 2027
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Corrie Lipids Digital Health ProgramN/A
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular RiskN/A1 trial
Active Trials
NCT01781416Completed799Est. Apr 2014
Innovation Pharmaceuticals
1 program
Yerba mate teaN/A1 trial
Active Trials
NCT06729905Completed52Est. May 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Novo NordiskZiltivekimab
Novo NordiskZiltivekimab B
NewAmsterdam PharmaCorrie Lipids Digital Health Program
Novo NordiskNo treatment given
AstraZenecaLevel of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk
Innovation PharmaceuticalsYerba mate tea

Clinical Trials (6)

Total enrollment: 36,249 patients across 6 trials

NCT06118281Novo NordiskZiltivekimab

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Start: Jun 2024Est. completion: Dec 202610,000 patients
Phase 3Recruiting
NCT05021835Novo NordiskZiltivekimab B

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Start: Aug 2021Est. completion: Jun 20266,200 patients
Phase 3Active Not Recruiting
NCT07478887NewAmsterdam PharmaCorrie Lipids Digital Health Program

Impact of the Corrie Lipids Digital Health Program on Lipid Optimization

Start: Jun 2025Est. completion: Dec 20271,000 patients
N/ARecruiting
NCT06122961Novo NordiskNo treatment given

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

Start: Nov 2023Est. completion: Apr 202518,198 patients
N/ACompleted
NCT01781416AstraZenecaLevel of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk

Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk

Start: Nov 2013Est. completion: Apr 2014799 patients
N/ACompleted
NCT06729905Innovation PharmaceuticalsYerba mate tea

Study of the Effects of Yerba Mate on Cardiometabolic Health

Start: Jan 2012Est. completion: May 201552 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 36,249 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.